Lifecore Biomedical (LFCR) Expected to Announce Quarterly Earnings on Thursday

Lifecore Biomedical (NASDAQ:LFCR) is expected to be issuing its Q2 2026 results after the market closes on Thursday, January 1st. Analysts expect Lifecore Biomedical to post earnings of ($0.11) per share and revenue of $35.3080 million for the quarter. Investors may review the information on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Friday, January 9, 2026 at 12:00 AM ET.

Lifecore Biomedical (NASDAQ:LFCR) last announced its quarterly earnings results on Monday, April 1st. The company reported ($0.22) EPS for the quarter. The firm had revenue of $26.54 million during the quarter. Lifecore Biomedical had a negative net margin of 25.59% and a negative return on equity of 1,211.09%. On average, analysts expect Lifecore Biomedical to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Lifecore Biomedical Stock Down 0.6%

Shares of LFCR stock opened at $8.25 on Tuesday. Lifecore Biomedical has a 52-week low of $4.76 and a 52-week high of $8.85. The stock has a market cap of $309.13 million, a price-to-earnings ratio of -7.71 and a beta of 0.60. The firm’s 50-day moving average is $7.58 and its 200-day moving average is $7.48. The company has a debt-to-equity ratio of 113.76, a quick ratio of 1.67 and a current ratio of 2.80.

Wall Street Analysts Forecast Growth

LFCR has been the subject of several research analyst reports. KeyCorp initiated coverage on Lifecore Biomedical in a research note on Wednesday, September 3rd. They set a “sector weight” rating for the company. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Lifecore Biomedical in a research report on Wednesday, October 8th. One investment analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Lifecore Biomedical has a consensus rating of “Hold” and an average price target of $6.00.

Institutional Investors Weigh In On Lifecore Biomedical

A number of institutional investors have recently modified their holdings of the business. Quarry LP bought a new position in Lifecore Biomedical in the third quarter valued at approximately $28,000. BNP Paribas Financial Markets boosted its holdings in shares of Lifecore Biomedical by 92.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 5,791 shares of the company’s stock valued at $43,000 after purchasing an additional 2,786 shares in the last quarter. State of Wyoming acquired a new position in shares of Lifecore Biomedical during the 2nd quarter worth $69,000. The Manufacturers Life Insurance Company bought a new stake in shares of Lifecore Biomedical during the 2nd quarter worth $88,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Lifecore Biomedical by 14.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 14,785 shares of the company’s stock valued at $104,000 after buying an additional 1,886 shares in the last quarter. Institutional investors own 83.36% of the company’s stock.

Lifecore Biomedical Company Profile

Lifecore Biomedical, Inc is a publicly traded specialty biopharmaceutical company headquartered in Chaska, Minnesota. The company focuses on the development, manufacture and commercialization of hyaluronic acid (HA)–based products that address medical and aesthetic needs. Lifecore’s proprietary HA formulations are designed to meet strict regulatory standards for purity, consistency and performance in highly regulated markets.

The company’s product portfolio spans multiple therapeutic areas, including ophthalmology, orthopedics, dermatology and wound care.